Sentence examples for face patent from inspiring English sources

The Bristol-Myers Squibb drug, Pravachol, does not face patent expiration until 2005.

Merck & Company warned yesterday that sales of three older medicines that face patent expirations would fall sharply in 2001, but that the loss would be offset by revenue from five newer medicines.

Glaxo's portfolio would gain longevity with Selzentry, a new H.I.V. drug from Pfizer that does not face patent expiry in the United States until 2021, as well as several drugs Pfizer has under development.

Moreover, several biotech drugs now face patent expiry and regulatory issues in both Europe and America permitting may soon offer another source of business for Sandoz, which already sells one such "biosimilar" drug in Australia.Only a few years ago big drug firms, which had bought generics companies in the hope of making easy money, were busy trying to off-load them.

Eli Lilly & Co., which in the next decade would face patent expiration on drugs making up nearly 75% of its current sales, was hoping to fill the gap with new drugs treating cancer and Alzheimer disease, though in August it halted development of the latter after poor test-studies results.

And a newer one: some blockbuster biotech products will face patent expiry and generic competition over the next couple of years, first in Europe and then probably in America too.Nor is the biotech industry immune to the safety problems that have plagued big pharmaceutical firms.

AbbVie faces patent expiry on its main product, Humira for rheumatoid arthritis, the world's top-selling medicine.

Mr. Soriot acknowledged that his new job would be a challenge, as the entire industry faces patent losses and pressure on prices.

UCB, which faces patent expirations on its top sellers starting next year, will get three drugs that may provide more than 2 billion euros in annual revenue.

AstraZeneca is not alone in the pharma business in facing patent expiries, the consequences of a squeeze from government healthcare spending and smaller pipelines of new products.

In fact, we could go through a period where a number of these companies that are facing patent expirations will perform better than expected.